Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 5 mg) |
| Drug Class | Dipeptidyl peptidase-4 inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Linagliptin (Tradjenta) is recommended alongside diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus.
- The information comes from an analysis of 13 systematic reviews/meta-analyses concerning the efficacy and safety profile of linagliptin, especially in comparison with other glucose-lowering drugs.
- In children and adolescents, linagliptin significantly lowers HbA1c levels, but it is less effective than saxagliptin+metformin, liraglutide+metformin, and liraglutide alone.
- Used in combination with empagliflozin, linagliptin achieves better results in reducing HbA1c and fasting plasma glucose than when either drug is used alone.
- Linagliptin has proven effective among Asian patients with type 2 diabetes, including those in the East Asian subgroup, indicating its global applicability in adult populations.
- Although demonstrating a low risk for adverse events among Asian patients with type 2 diabetes, and overall tolerance being good, there is an association between DPP4 inhibitors like linagliptin and an increased risk of developing bullous pemphigoid, which requires cautious use.
- Cardiovascular safety outcomes are favorable, without any associated increase in overall cancer risks, even suggesting a possible beneficial effect on reducing the risk of colorectal cancer, but further research is needed to compare linagliptin with gliclazide regarding major adverse cardiovascular events and hypoglycemia risks among adult type 2 diabetes patients without a history of cardiovascular disease.
- Linagliptin may have a positive impact on endothelial function and arterial wall properties, with an observed neutral effect towards macrovascular complications, not affecting microvascular complications, except for possibly slowing the progression of albuminuria; additional trials are necessary to confirm these potential benefits.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tradjenta (linagliptin) Prescribing Information. | 2023 | Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT |